MX2022003044A - Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer. - Google Patents

Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.

Info

Publication number
MX2022003044A
MX2022003044A MX2022003044A MX2022003044A MX2022003044A MX 2022003044 A MX2022003044 A MX 2022003044A MX 2022003044 A MX2022003044 A MX 2022003044A MX 2022003044 A MX2022003044 A MX 2022003044A MX 2022003044 A MX2022003044 A MX 2022003044A
Authority
MX
Mexico
Prior art keywords
cancer
targeting drug
phospholipid ether
drug vehicles
therapeutic compounds
Prior art date
Application number
MX2022003044A
Other languages
English (en)
Inventor
Jarrod Longcor
Anatoly Pinchuk
Randall Hoover
Zhongping Huang
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Publication of MX2022003044A publication Critical patent/MX2022003044A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Abstract

Se describen en la presente compuestos terapéuticos capaces de focalizar una amplia gama de células tumorales; la presente descripción está dirigida además a composiciones que comprenden los compuestos terapéuticos, métodos de fabricación de los compuestos terapéuticos, y métodos para tratar el cáncer, que comprenden administrar los compuestos terapéuticos.
MX2022003044A 2019-09-12 2020-09-11 Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer. MX2022003044A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962899618P 2019-09-12 2019-09-12
US201962899611P 2019-09-12 2019-09-12
US201962899615P 2019-09-12 2019-09-12
US201962946870P 2019-12-11 2019-12-11
US202062956907P 2020-01-03 2020-01-03
US202062956844P 2020-01-03 2020-01-03
PCT/US2020/050459 WO2021050917A1 (en) 2019-09-12 2020-09-11 Phospholipid ether conjugates as cancer-targeting drug vehicles

Publications (1)

Publication Number Publication Date
MX2022003044A true MX2022003044A (es) 2022-06-02

Family

ID=74866023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003044A MX2022003044A (es) 2019-09-12 2020-09-11 Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.

Country Status (11)

Country Link
US (1) US20230066517A1 (es)
EP (1) EP4028018A4 (es)
JP (1) JP2022547331A (es)
KR (1) KR20220062363A (es)
CN (1) CN114599371A (es)
AU (1) AU2020346898A1 (es)
BR (1) BR112022004482A2 (es)
CA (1) CA3150991A1 (es)
IL (1) IL291197A (es)
MX (1) MX2022003044A (es)
WO (1) WO2021050917A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113816990B (zh) * 2021-03-22 2023-08-22 联宁（苏州）生物制药有限公司 修饰的氨基酸及其在adc中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) * 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
EP2475400A2 (en) * 2009-09-11 2012-07-18 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
SI3229810T1 (sl) * 2014-11-17 2021-01-29 Cellestar Biosciences, Inc. Analogi fosfolipidnega etra kot vehikli zdravil, usmerjenih proti raku
SI3469367T1 (sl) * 2016-06-14 2023-10-30 Cellectar Biosciences, Inc. Analogi fosfolipidnega etra za identifikacijo in izolacijo tumorskih celic v obtoku
CA3095515A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Also Published As

Publication number Publication date
WO2021050917A1 (en) 2021-03-18
EP4028018A4 (en) 2023-10-11
EP4028018A1 (en) 2022-07-20
US20230066517A1 (en) 2023-03-02
BR112022004482A2 (pt) 2022-05-31
CA3150991A1 (en) 2021-03-18
IL291197A (en) 2022-05-01
CN114599371A (zh) 2022-06-07
AU2020346898A1 (en) 2022-04-07
JP2022547331A (ja) 2022-11-11
KR20220062363A (ko) 2022-05-16

Similar Documents

Publication Publication Date Title
JOP20210074A1 (ar) مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
MX2017006382A (es) Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer.
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
WO2020236825A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
MX2015011583A (es) Derivados de amatoxina.
SG10201907684PA (en) Androgen receptor modulator and uses thereof
MX2019010202A (es) Compuestos que interactuan con glicano y metodos de uso.
BR112012014569A8 (pt) métodos e composições para destruição de tumores
BR112013004698A2 (pt) composições farmacêuticas compreendendo derivados de poh
MX2019001302A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
MD4643B1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
HK1071310A1 (en) Combination therapy for the treatment of cancer
TW201613589A (en) Combination methods for treating cancers
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
CY1125126T1 (el) Θεραπεια συνδυασμου αναστολεα βρωμοεπικρατειας και επιπλεον-τερματικης πρωτεϊνης
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
JOP20200244A1 (ar) مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان
MX2023007162A (es) Macrociclos y sus usos.
MX2023000503A (es) Macrociclos y su uso.
MX2022003044A (es) Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.
MX2021001832A (es) Conjugados para su uso en metodos de tratamiento del cancer.
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
MX2019003258A (es) Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.
WO2014062587A3 (en) Injectable cancer compositions
MX2020010741A (es) Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer.